|
Alcon's Systane®, the first eye drop clinically proven to provide long-lasting relief from both signs and symptoms of dry eyes, and VIGAMOX® solution, an antibiotic used to treat the most common eye infection, bacterial conjunctivitis (commonly called "pink eye").
|
| |
Leading eyecare company, Alcon, Inc., has announced its intentions to build a pharmaceutical manufacturing facility in Singapore to meet the increasing demand for its products.
In Asia, sales of Alcon's major brands such as TRAVATAN®, PATANOL® and VIGAMOX® ophthalmic solutions, TOBRADEX® ophthalmic ointment and Systane® eye drops are rising at a compound annual growth rate of more than 20 per cent. The new plant will enable the company to be more efficient and cost-effective in its distribution of pharmaceuticals throughout Asia, helping it to better meet the increased demand.
"Given the solid growth in this region, this plant is integral to our ability to meet future market demands," says Ed McGough, Senior Vice President, Global Manufacturing and Technical Operations, Alcon. "After a lengthy and careful analysis of potential plant locations and through close collaboration with the Singapore Economic Development Board (EDB), we selected Singapore due to its highly skilled and reliable workforce and well-established government infrastructure."
To be located in Tuas Biomedical Park, the 250,000 sq ft facility is scheduled to be fully functional in 2012. The company expects to manufacture at a rate of more than 53 million units per year at this facility and employ more than 150 employees by the end of the third year of operation.
"Alcon's investment bears testimony to Singapore's track record in manufacturing excellence, regulatory compliance, excellent logistics and strong intellectual property protection," says Aw Kah Peng, Assistant Managing Director, Industry Development, EDB. "This new facility will be a welcome addition to the growing cluster of pharmaceutical and biotechnology plants in Tuas Biomedical Park."
|
|
|
